AKTX — Akari Therapeutics PLC

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Akari Therapeutics PLC

Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bl… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$14.63
Market Cap$26.1M
Float41.33B
Shares Outstanding1.1M
Price/Sales (TTM)478,368.50
vs. Analyst Target+83.0% to analyst PT
Dividend RateNone
Analyst Target Price$26.78 (1 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$17.1M -$8,907 -$18.0M
2021 N/A -$17.4M -$4,126 -$17.2M
2022 N/A -$17.7M -$3,708 -$23.1M
2023 N/A -$10.0M -$4,000 -$16.8M
2024 N/A -$19.8M -$13,999 -$19.5M
2025 N/A -$17.3M N/A -$17.4M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$1.9M
Sep 2025 N/A -$6.4M
Dec 2025 N/A -$5.3M
Mar 2026 N/A -$14.5M

Ownership & Float

Insider Ownership24.6%
Institutional Ownership5.9%
Short Float0.0%
% of All Funds Holding0.07%
Number of Funds Holding6

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$8.44Near-term / short-term trend
Weekly40-Week SMA$16.03Medium-term trend
Weekly80-Week SMA$30.87Cyclical trend (business cycle)
Weekly200-Week SMA$143.95Secular trend (multi-year)
Monthly10-Month SMA$16.18Near-term monthly trend
Monthly20-Month SMA$30.85Medium-term monthly trend
Monthly40-Month SMA$77.05Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$5.60 support 9.22x 0 months ago
$19.10 resistance 6.82x 5 months ago
$30.40 resistance 3.52x 6 months ago
$39.60 resistance 1.50x 7 months ago
$41.00 resistance 1.23x 9 months ago

Historical Earnings Reactions (40 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.30% 0.00% 45.00% 15.03% -15.38%
1 Day 0.13% -0.08% 45.00% 49.85% -16.92%
1 Week 21.71% -0.19% 47.50% 508.46% -23.41%
2 Weeks 6.02% -0.32% 43.59% 247.69% -32.71%
1 Month 5.18% -5.82% 46.15% 223.08% -52.06%

Next earnings: May 13, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan0.7%41.7%12
Feb-17.4%23.1%13
Mar5.1%38.5%13
Apr5.3%46.2%13
May1.5%23.1%13
Jun5.0%50.0%12
Jul2.4%33.3%12
Aug23.1%50.0%12
Sep4.7%50.0%12
Oct-13.1%25.0%12
Nov-7.2%41.7%12
Dec-9.7%25.0%12

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.26% 44.6% 583
Tuesday -0.39% 39.0% 643
Wednesday 0.81% 41.3% 640
Thursday -0.57% 36.0% 627
Friday 0.73% 43.5% 625

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 5.9%

Insider Transactions — Smart Summary

Total insider ownership: 24.6%

12-Month Insider Activity Summary

Total Filings4
Net Value+$56,660.641
Net Shares Change52,146
% of Float0.0%
C-Suite Filings4
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Gaslightwala Abizer CEO +$56,660.641 4 4 buy

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-08-29 Gaslightwala Abizer CEO +$19,540.5 Transaction at $0.93, now +1472.3%
2025-06-20 Gaslightwala Abizer President and CEO +$18,000 Transaction at $1.20, now +1119.2%
2025-06-25 Gaslightwala Abizer President and CEO +$7,120.141 Transaction at $1.16, now +1162.8%
2025-06-24 Gaslightwala Abizer President and CEO +$12,000 Transaction at $1.20, now +1119.2%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Akari Therapeutics PLC (AKTX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for AKTX on Trend Edge →